Full Press Release Details
IDEAYA Announces IND Clearance Enabling Phase 1 2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP Deletion Solid Tumors.
IDYA
IDEAYA Announces IND Clearance Enabling Phase 1 2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP Deletion Solid Tumors
Key Takeaway: IDEAYA Announces IND Clearance Enabling Phase 1 2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP Deletion Solid Tumors
Price reaction · baseline $21.77 (2023-05-19 close) · clean, no other IDYA news in the window
day 0 close · peak
+2.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma